epocrates logo
epocrates logo
epocrates logo
  • 0

Herbs & Supplements

epocrates logo

Sign in to access our clinical decision support tools

Sign in Create Account

Formulary
No Formulary Selected

close

 

Select a medication above to begin.

marine lipid concentrate

fish oil

Sections:

  • Entire Monograph
  • Reported Uses
  • Reported Doses
  • Cautions
  • Drug Interactions
  • Adverse Reactions
  • Synonyms
  • Other Info
  • Add to Interaction Check

Reported Uses

  • NOTE: see Herb & Supplement Effectiveness Rating Definitions table
  • ADHD [Insufficient Evidence]
  • age-related macular degeneration [Possibly Ineffective]
  • allergic rhinitis prevention [Insufficient Evidence]
  • Alzheimer disease [Insufficient Evidence]
  • angina [Possibly Ineffective]
  • aphthous ulcer (canker sores) [Insufficient Evidence]
  • ARDS [Insufficient Evidence]
  • asthma [Insufficient Evidence]
  • atherosclerosis [Possibly Ineffective]
  • athletic performance [Insufficient Evidence]
  • atopic dermatitis (eczema) [Possibly Ineffective]
  • atopic disease [Insufficient Evidence]
  • atrial fibrillation [Possibly Ineffective]
  • autism spectrum disorder [Insufficient Evidence]
  • autoimmune thyroiditis prevention [Insufficient Evidence]
  • bipolar disorder [Insufficient Evidence]
  • bone loss, renal transplant-related [Insufficient Evidence]
  • borderline personality disorder [Insufficient Evidence]
  • bronchopulmonary dysplasia [Possibly Ineffective]
  • burns [Insufficient Evidence]
  • CABG [Insufficient Evidence]
  • cachexia, cancer-related [Possibly Effective]
  • cancer prevention [Insufficient Evidence]
  • cardiovascular disease prevention [Insufficient Evidence]
  • cataracts [Insufficient Evidence]
  • cerebrovascular disease prevention [Possibly Ineffective]
  • cirrhosis [Insufficient Evidence]
  • CKD [Insufficient Evidence]
  • cognitive decline, age-related [Insufficient Evidence]
  • cognitive function [Possibly Ineffective]
  • cognitive impairment, mild [Insufficient Evidence]
  • colorectal CA [Insufficient Evidence]
  • COPD [Insufficient Evidence]
  • COVID-19 [Insufficient Evidence]
  • Crohn disease [Insufficient Evidence]
  • cystic fibrosis [Insufficient Evidence]
  • dementia [Insufficient Evidence]
  • depression [Insufficient Evidence]
  • developmental coordination disorder [Insufficient Evidence]
  • diabetes mellitus [Likely Ineffective]
  • diabetic nephropathy [Insufficient Evidence]
  • diabetic neuropathy [Insufficient Evidence]
  • diabetic retinopathy [Insufficient Evidence]
  • dry eye disease [Insufficient Evidence]
  • dyslexia [Insufficient Evidence]
  • dyslipidemia [Insufficient Evidence]
  • dyslipidemia, HIV/AIDS-related [Possibly Effective]
  • dysmenorrhea [Possibly Effective]
  • endometriosis [Insufficient Evidence]
  • epilepsy [Insufficient Evidence]
  • exercise-induced muscle soreness [Insufficient Evidence]
  • food allergies [Insufficient Evidence]
  • frailty [Insufficient Evidence]
  • gingivitis [Insufficient Evidence]
  • glaucoma [Insufficient Evidence]
  • heart failure [Possibly Effective]
  • heart transplant [Insufficient Evidence]
  • hemodialysis graft dysfunction [Insufficient Evidence]
  • H. pylori infection [Possibly Ineffective]
  • HIV/AIDS [Insufficient Evidence]
  • HTN [Possibly Effective]
  • HTN, cyclosporine-induced [Insufficient Evidence]
  • HTN, pregnancy-induced [Possibly Ineffective]
  • hypertriglyceridemia [Effective]
  • IgA nephropathy [Possibly Effective]
  • impaired glucose tolerance [Insufficient Evidence]
  • infant development [Insufficient Evidence]
  • insomnia [Insufficient Evidence]
  • intrauterine growth restriction [Insufficient Evidence]
  • joint pain [Insufficient Evidence]
  • lung CA [Insufficient Evidence]
  • Lyme disease [Insufficient Evidence]
  • male infertility [Insufficient Evidence]
  • mastalgia [Possibly Ineffective]
  • melanoma [Insufficient Evidence]
  • menopausal symptoms [Insufficient Evidence]
  • metabolic dysfunction-associated steatotic liver disease [Possibly Effective]
  • metabolic effects, antipsychotic-induced [Insufficient Evidence]
  • migraine prophylaxis [Insufficient Evidence]
  • miscarriage prevention, antiphospholipid syndrome-associated [Insufficient Evidence]
  • multiple sclerosis [Possibly Ineffective]
  • muscle strength [Insufficient Evidence]
  • nausea/vomiting, gastroenteritis-related [Possibly Effective]
  • nephrolithiasis [Insufficient Evidence]
  • nephropathy, contrast-induced [Insufficient Evidence]
  • nephrotoxicity, cyclosporine-induced [Possibly Effective]
  • obesity [Insufficient Evidence]
  • oral mucositis [Insufficient Evidence]
  • osteoarthritis [Possibly Ineffective]
  • osteoporosis [Insufficient Evidence]
  • Parkinson disease [Insufficient Evidence]
  • periodontitis [Insufficient Evidence]
  • peripheral arterial disease [Insufficient Evidence]
  • peripheral neuropathy, chemo-induced [Insufficient Evidence]
  • phenylketonuria [Insufficient Evidence]
  • pneumonia prevention [Insufficient Evidence]
  • polycystic ovary syndrome [Insufficient Evidence]
  • polymyalgia rheumatica prevention [Insufficient Evidence]
  • postmenopausal conditions [Insufficient Evidence]
  • postop fistula [Insufficient Evidence]
  • postop infection [Insufficient Evidence]
  • postop recovery [Insufficient Evidence]
  • postpartum depression [Insufficient Evidence]
  • post-traumatic stress disorder [Insufficient Evidence]
  • pre-eclampsia [Possibly Ineffective]
  • prematurity [Insufficient Evidence]
  • pressure ulcer [Insufficient Evidence]
  • preterm labor prevention [Insufficient Evidence]
  • prostate CA [Insufficient Evidence]
  • pruritus [Insufficient Evidence]
  • psoriasis [Insufficient Evidence]
  • psychosis [Possibly Ineffective]
  • PTCA restenosis prevention [Possibly Effective]
  • Raynaud phenomenon [Insufficient Evidence]
  • renal failure [Insufficient Evidence]
  • renal transplant [Possibly Ineffective]
  • rheumatoid arthritis [Possibly Effective]
  • salicylate intolerance [Insufficient Evidence]
  • sarcopenia [Insufficient Evidence]
  • schizophrenia [Insufficient Evidence]
  • sepsis [Insufficient Evidence]
  • sickle cell disease [Insufficient Evidence]
  • Sjogren syndrome [Insufficient Evidence]
  • SLE [Insufficient Evidence]
  • stroke prevention [Insufficient Evidence]
  • tinnitus prevention [Insufficient Evidence]
  • ulcerative colitis [Insufficient Evidence]
  • URI [Insufficient Evidence]
  • venous thromboembolism prophylaxis [Insufficient Evidence]
  • ventricular arrhythmias [Possibly Ineffective]
  • vitamin D deficiency [Insufficient Evidence]

Copyright © 2026. All Rights Reserved. Republication or redistribution, including by framing or similar means, is prohibited without the prior written consent of copyright holder.

Select a medication above to begin.

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information